<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101231005</journal-id>
<journal-id journal-id-type="pubmed-jr-id">32413</journal-id>
<journal-id journal-id-type="nlm-ta">Pharmacogenet Genomics</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacogenet. Genomics</journal-id>
<journal-title-group>
<journal-title>Pharmacogenetics and genomics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1744-6872</issn>
<issn pub-type="epub">1744-6880</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26736087</article-id>
<article-id pub-id-type="pmc">4935646</article-id>
<article-id pub-id-type="doi">10.1097/FPC.0000000000000202</article-id>
<article-id pub-id-type="manuscript">NIHMS744381</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>PGRNseq: A Targeted Capture Sequencing Panel for Pharmacogenetic Research and Implementation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gordon</surname>
<given-names>Adam</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fulton</surname>
<given-names>Robert S.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qin</surname>
<given-names>Xiang</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mardis</surname>
<given-names>Elaine R.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nickerson</surname>
<given-names>Deborah A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scherer</surname>
<given-names>Steve</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Genome Sciences, University of Washington</aff>
<aff id="A2"><label>2</label> The Baylor College of Medicine Human Genome Sequencing Center, Houston, TX</aff>
<aff id="A3"><label>3</label>The Genome Institute at Washington University, St. Louis, MO</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Corresponding author: <email>debnick@uw.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>17</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>05</day>
<month>7</month>
<year>2017</year>
</pub-date>
<volume>26</volume>
<issue>4</issue>
<fpage>161</fpage>
<lpage>168</lpage>
<!--elocation-id from pubmed: 10.1097/FPC.0000000000000202-->
<abstract>
<sec id="S1">
<title>Objectives</title>
<p id="P1">While the costs associated with whole-genome and whole-exome next-generation sequencing continue to decline, they remain prohibitively expensive for large-scale studies of genetic variation. As an alternative, custom-target sequencing has become a common methodology based on its favorable balance between cost, throughput, and deep coverage.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">We have developed PGRNseq, a custom-capture panel of 84 genes with associations to pharmacogenetic phenotypes, as a tool to explore the relationship between drug response and genetic variation, both common and rare. We utilized a set of 32 diverse HapMap trios and 2 clinical cohorts to assess platform performance, accuracy, and ability to discover novel variation.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">We find that PGRNseq generates ultra-deep coverage data (mean = 496x) that is over 99.8% concordant with orthogonal datasets. Additionally, in our testing sets, PGRNseq identified many novel, rare variants of interest, underscoring its value in both research and clinical settings.</p>
</sec>
<sec id="S4">
<title>Conclusion</title>
<p id="P4">PGRNseq is an ideal platform for performing sequencing-based analyses of pharmacogenetic variation in large cohorts. Additionally, the high accuracy associated with genotypes from PGRNseq highlight its utility as a clinical test.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Pharmacogenomics</kwd>
<kwd>Targeted Sequencing</kwd>
<kwd>Rare Variation</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>